Clinical Trials Browser

Has results × Lymphoma, Follicular × ofatumumab × Clear all

NCT01190449 2021-08-18

Ofatumumab in Treating Patients With Previously Untreated Stage II, Stage III, or Stage IV Follicular Non-Hodgkin Lymphoma

Phase 2 Completed

51 enrolled 7 charts

Lymphoma, Lymphoma, Follicular

NCT01077518 2020-03-27

A+B

Phase 3 Terminated

346 enrolled 41 charts

Lymphoma, Follicular, Neoplasms

NCT01119794 2015-08-26

Ofatumumab and Bortezomib for Patients With Low-grade B-cell Non-hodgkin Lymphoma That Relapse After Rituximab

Phase 2 Terminated

10 enrolled 7 charts

LymphoidOther hematologic neoplasm

Lymphoma, Follicular, Lymphoma, Non-Hodgkin, Waldenstrom Macroglobulinemia, Leukemia, B-Cell, Lymphoma, B-Cell, Marginal Zone, Lymphoma, Mantle-Cell

NCT01397591 2014-07-30

Ofatumumab and Bortezomib in Subjects With Relapsed CD20+Diffuse Large B Cell, Follicular, or Mantle Cell Lymphoma

Phase 2 Terminated

3 enrolled 6 charts

Lymphoma, Follicular, Lymphoma, Large B-Cell, Diffuse, Lymphoma, Mantle-Cell

NCT00494780 2014-07-11

MUNIN

Phase 2 Completed

59 enrolled 21 charts

Lymphoma, Follicular

NCT00394836 2014-01-29

HuMax-CD20 i(Ofatumumab) n Follicular Lymphoma (FL) Patients Refractory to Rituximab

Phase 2 Completed

116 enrolled 22 charts

Lymphoma, Follicular